Washington D.C. [USA], April 27 (ANI): In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a